BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
30 nov. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
28 nov. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
07 nov. 2023 16h01 HE
|
BioAtla, Inc.
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be...
BioAtla to Participate in the Jefferies London Healthcare Conference
06 nov. 2023 16h05 HE
|
BioAtla, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
12 oct. 2023 07h30 HE
|
BioAtla, Inc.
SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
10 oct. 2023 07h30 HE
|
BioAtla, Inc.
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion...
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in Upcoming Investor Conferences in August
03 août 2023 16h01 HE
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
01 août 2023 16h01 HE
|
BioAtla, Inc.
Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug...
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
25 juil. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...